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Tail suspension testConsidering that the administration of ascorbic acid elicits an antidepressant-effect in mice by a mechanism
which involves an interaction with N-methyl-D-aspartate receptors and the L-arginine-nitric oxide-cGMP
pathway and taking into account that the stimulation of this pathway is associated with the activation of po-
tassium (K+) channels, this study investigated the involvement of different types of K+ channels on the ef-
fect of ascorbic acid in the mouse tail suspension test (TST). Intracerebroventricular administration of
tetraethylammonium (TEA, a non-speciﬁc blocker of K+ channels, 25 pg/site), glibenclamide (an ATP-
sensitive K+ channel blocker, 0.5 pg/site), charybdotoxin (a large- and intermediate conductance calcium-
activated K+ channel blocker, 25 pg/site) or apamin (a small-conductance calcium-activated K+ channel
blocker, 10 pg/site) was able to produce a synergistic effect with a sub-effective dose of ascorbic acid
(0.1 mg/kg) given orally (p.o.). The antidepressant-like effect of ascorbic acid (1 mg/kg, p.o.) in the TST
was prevented by the pre-treatment of mice with cromakalim (a K+ channel opener, 10 μg/site, i.c.v.) and
minoxidil (10 μg/site, i.c.v.). Moreover, cromakalim abolished the synergistic effect elicited by the combined
treatment with sub-effective doses of ascorbic acid and 7-nitroindazole. The administration of the K+ chan-
nel modulators alone or in combination with ascorbic acid did not affect the locomotion of mice. Together,
our results show that the antidepressant-like effect of ascorbic acid in the TST may involve, at least in part,
the modulation of neuronal excitability, via inhibition of K+ channels.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Depression is a debilitating and highly prevalent disorder that af-
fects individuals worldwide and causes a signiﬁcant negative impact
on public health. Although a range of antidepressants with varied
mechanisms of action are available, a considerable number of patients
exhibit partial, refractory or intolerant responses to the pharmacolog-
ical treatment. Ascorbic acid, a water-soluble vitamin with neuro-
protective and antioxidant properties (Rice, 2000), is emerging as a
novel putative compound to assist in the treatment of depression. In
clinical studies, it was reported that the administration of ascorbic
acid relieved adrenocorticotropic hormone-induced depression in a
child (Cocchi et al., 1980) and decreased scores in a Beck Depression
Inventory in healthy young adults (Brody, 2002), indicating mood im-
provement. In mice, the administration of ascorbic acid produced an
antidepressant-like effect in the tail suspension test (TST) by a mech-
anism that is dependent on the interaction of this vitamin with the
monoaminergic systems (Binfaré et al., 2009), N-Methyl-D-aspartate
(NMDA) receptors and the L-arginine-nitric oxide (NO)-cyclic
guanosine monophosphate (cGMP) pathway (Moretti et al., 2011).: +55 48 3721 9672.
gmail.com (A.L.S. Rodrigues).
evier OA license.Reinforcing the notion that this vitamin may be an alternative
approach in the management of depression symptoms, our group
recently demonstrated that repeated ascorbic acid treatment,
similar to ﬂuoxetine, reversed depressive-like behavior and brain ox-
idative damage induced by chronic unpredictable stress in mice
(Moretti et al., 2012).
Several subtypes of potassium (K+) channels with different phar-
macological sensitivities and electro-physiological characteristics
have been reported in neurons (Aronson, 1992; Halliwell, 1990).
These channels are important regulators of physiological processes
which include the regulation of neuronal excitability and signal prop-
agation (MacKinnon, 2003; Shieh et al., 2000). The association of K+
channels with the pathophysiology of depression has been suggested
by several preclinical studies. The administration of a variety of K+
channel blockers, such as tetraethylammonium (TEA), apamin,
charybdotoxin, gliquidone and glibenclamide, were reported to pro-
duce an antidepressant-like effect in the forced swimming test
(Galeotti et al., 1999; Kaster et al., 2005), whereas the treatment
with K+ channel openers, such as minoxidil or cromakalim, increased
the immobility time in this test, indicative of a depressive-like effect
(Galeotti et al., 1999). Moreover, literature data suggest that different
classes of antidepressants, including ﬂuoxetine, venfalaxine, imipra-
mine, desipramine, amitriptyline, nortriptyline, clomipramine,
maprotiline, citalopram and paroxetine may modulate neuronal
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common pathway of the pharmacological action of these drugs
(Bortolatto et al., 2010; Kobayashi et al., 2004, 2006; Nicholson et
al., 2002; Tytgat et al., 1997).
Some studies have reported that both NO and cGMP, produced
through the activation of nitric oxide synthase (NOS) and soluble
guanylate cyclase (sGC), respectively, can activate different types of
K+ channels in several tissues (Bolotina et al., 1994; H.J. Jeong et al.,
2001; S.Y. Jeong et al., 2001). In addition, NO donors are also capable
of activating these channels (Fujino et al., 1991;Williams et al., 1988).
Indeed, the inhibition of NMDA receptors with consequent reduction
in the NO levels prevents the activation of K+ channels, avoiding hy-
perpolarization of neurons and reducing the effectiveness of excitato-
ry inputs (Christie, 1995).
Given that the antidepressant-like effect of ascorbic acid in the TST
is dependent on the inhibition of either NMDA receptors or NO and
cGMP synthesis, we hypothesized that an inhibition of K+ channels
is implicated in its effect in the TST.
2. Material and methods
2.1. Animals
The behavioral experiments were conducted using adult Swiss
mice (2 months, 30–40 g) of either sex (homogeneously distributed
among groups), maintained at 20–22 °C with free access to water
and food, under a 12:12 h light/dark cycle, with lights on at
7:00 a.m. The animals were caged in groups of 15 in a 41×
34×16 cm cage and were placed in the experimental room 24 h be-
fore the test for acclimatization. All behavioral tests were carried
out between 09.00 a.m. and 04.00 p.m. The animals were used
according to the NIH Guide for the Care and Use of Laboratory Ani-
mals and the experiments were performed after approval of the pro-
tocol by the Ethics Committee of the Institution. All efforts were made
to minimize animal suffering and to reduce the number of animals
used in the experiments.
2.2. Drugs
The following drugs were used: ascorbic acid, TEA, 7-nitroindazole
(Sigma Chemical Co, USA), apamin, charybdotoxin, cromakalim, mi-
noxidil and glibenclamide (Tocris Cookson, Ballwin, MO, USA).
Cromakalim, minoxidil and 7-nitroindazole were dissolved in saline
with 10% Tween 80, ascorbic acid was dissolved in distilled water
and all the other drugs were dissolved in isotonic saline solution
(NaCl 0.9%) immediately before use. Appropriate vehicle-treated
groups were also assessed simultaneously. Most of the drugs were ad-
ministered by intracerebroventricular (i.c.v.) route, in a volume of 5 μl
per mouse, except ascorbic acid, which was administered orally (p.o.)
by gavage and 7-nitroindazole, which was administered intraperito-
neally (i.p.) in a constant volume of 10 ml/kg body weight.
The i.c.v. injections were performed by employing a “free hand”
method under light ether anesthesia according to the procedure de-
scribed previously (Brocardo et al., 2008; Kaster et al., 2012). Brieﬂy,
a 0.4 mm external diameter hypodermic needle attached to a cannu-
la, which was linked to a 25 μl Hamilton syringe, was inserted per-
pendicularly through the skull and no more than 2 mm into the
brain of each mouse. A volume of 5 μl was then administered into
the left lateral ventricle. The injection was given over 30 s, and the
needle remained in place for another 30 s in order to avoid the reﬂux
of the substances injected. The injection site was 1 mm to the left
from the mid-point on a line drawn through to the anterior base of
the ears. I.c.v. injections were performed by an experienced investiga-
tor, who frequently controlled the regularity and the success of injec-
tions using a methylene blue dye and who observed, after killing and
frontal brain sectioning that the injection was successful in more than95% of trials. Results from mice presenting cannula misplacement or
any signs of cerebral hemorrhage (b5%) were discarded from statisti-
cal analysis.
2.3. Pharmacological treatment
To test the hypothesis that the antidepressant-like effect of ascorbic
acid is mediated through the inhibition of K+ channels, distinct groups
of mice were pretreated with a sub-effective dose of ascorbic acid
(0.1 mg/kg, p.o.) or vehicle 45 min before the i.c.v. administration of
TEA (a non-speciﬁc blocker of K+ channels, 25 pg/site), glibenclamide
(an ATP-sensitive K+ channel blocker, 0.5 pg/site), charybdotoxin (a
large- and intermediate-conductance calcium-activated K+ channel
blocker, 25 pg/site), apamin (a small-conductance calcium-activated K+
channel blocker, 10 pg/site) or vehicle. A further 15 min were allowed
to elapse before the animals were tested in the TST. In another set of ex-
periments, mice were given an i.c.v. administration of cromakalim (a
K+ channel opener, 10 μg/site) or minoxidil (a K+ channel opener,
10 μg/site) 45 min after ascorbic acid administration (1 mg/kg, p.o.). Fif-
teen minutes later the TST was carried out.
In another experiment, we evaluated the effect of the adminis-
tration of a K+ channel opener on the antidepressant-like effect
elicited by the combined administration of sub-effective doses of
ascorbic acid and 7-nitroindazole (25 mg/kg, i.p., a neuronal NOS
inhibitor). To this end, ascorbic acid or vehicle was administered
30 min before 7-nitroindazole or vehicle. Fifteen minutes after
administration of 7-nitroindazole, mice were administered with
cromakalim (a K+ channel opener, 10 μg/site, i.c.v.) or vehicle and
15 min later they were tested in the TST.
The doses of ascorbic acid were selected according to previous
studies conducted in our laboratory (Binfaré et al., 2009; Moretti et
al., 2011). Doses and administration schedule of K+ channel modula-
tors were chosen based on literature data and on time-course and
dose–response experiments (Bortolatto et al., 2010; Budni et al.,
2007, 2012; Galeotti et al., 1999; Jesse et al., 2009; Kaster et al., 2005).
2.4. Behavioral tests
2.4.1. Tail suspension test
The total duration of immobility induced by tail suspension was
measured according to the method described by Steru et al. (1985).
Mice both acoustically and visually isolated were suspended 50 cm
above the ﬂoor by adhesive tape placed approximately 1 cm from
the tip of the tail. Mice were considered immobile only when they
hung passively and completely motionless. Immobility time was
manually recorded during a 6-min period by an experienced observ-
er. The observer was in the roomwhere experiments were performed
and was blind to the animal condition.
2.4.2. Open-ﬁeld test
Ten minutes after the tail suspension test, the locomotor activity
was assessed in an open-ﬁeld test as described previously (Moretti
et al., 2011). The apparatus consisted of a wooden box measuring
40×60×50 cm high. The ﬂoor of the arena was divided into 12
equal squares. The number of squares crossed with all paws (cross-
ings) was manually counted in a 6-min session. The light was
maintained at minimum to avoid anxiety behavior. The apparatus
were cleaned with a solution of 10% ethanol between tests in order
to hide animal clues.
2.5. Statistical analysis
All data are presented as mean±S.E.M. Differences among exper-
imental groups were determined by two- or three-way ANOVA
followed by Newman–Keuls post hoc test. A value of Pb0.05 was con-
sidered to be signiﬁcant.
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3.1. Effects of combined administration of sub-effective doses of the K+
channel blockers and ascorbic acid in the TST and open-ﬁeld test
Fig. 1 A shows the effect of the administration of sub-effective
doses of ascorbic acid and TEA (a non speciﬁc blocker of K+ channels,
25 pg/site) in the TST. The two-way ANOVA revealed signiﬁcant dif-
ferences for ascorbic acid [F(1,24)=10.85, Pb0.01], TEA [F(1,24)=
5.11, P=0.03] and ascorbic acid×TEA interaction [F(1,24)5.33,
P=0.02]. Post hoc analysis indicated that the treatment with ascorbic
acid produced a synergistic antidepressant-like effect with TEA. Re-
garding locomotor activity, the two-way ANOVA revealed no differ-
ences for ascorbic acid [F(1,25)=0.80, P=0.37], TEA [F(1,25)=
0.46, P=0.50], and ascorbic acid×TEA interaction [F(1,25)=2.39,
P=0.13] (Fig. 1B).
The results depicted in Fig. 1C show that glibenclamide (an ATP-
sensitive K+ channel blocker, 0.5 pg/site) was also able to produce a
synergistic action with a sub-effective dose of ascorbic acid in the
TST. The two-way ANOVA revealed signiﬁcant differences for
ascorbic acid [F(1,27)=12.28, Pb0.01], glibenclamide [F(1,27)=
7.67, Pb0.01] and ascorbic acid×glibenclamide interaction [F(1,27)=
11.71, Pb0.01]. Post hoc analysis indicated that the treatment with
ascorbic acid produced a synergistic antidepressant-like effect with
glibenclamide in the TST. In addition, the administration of glibenclamide
alone or in combination with ascorbic acid did not affect the locomotion
of mice (Fig. 1D). The two-way ANOVA revealed no differences for
ascorbic acid [F(1,27)=1.04, P=0.31], glibenclamide [F(1,27)=0.49,
P=0.48] and ascorbic acid x glibenclamide interaction [F(1,27)=0.42,
P=0.51] in the locomotor activity.
As presented in Fig. 2A, the administration of charybdotoxin (a large-
and intermediate conductance calcium-activated K+ channel blocker,
25 pg/site, i.c.v.) produced a synergistic antidepressant-like effect when
combined with a sub-effective dose of ascorbic acid in the TST. The two-Fig. 1. Effect of the treatment of mice with TEA (25 pg/site, i.c.v.) or glibenclamide (0.5 pg/s
the TST (panels A and C) and in the open-ﬁeld test (panels B and D). Values are expressed away ANOVA revealed signiﬁcant differences for ascorbic acid [F(1,24)=
6.46, P=0.01], charybdotoxin [F(1,24)=14.76, Pb0.01] and ascorbic
acid×charybdotoxin interaction [F(1,24)=11.05, Pb0.01]. Post hoc anal-
ysis indicated that the pre-treatmentwith a sub-effective dose of ascorbic
acid produced a synergistic effect with charybdotoxin in the TST. Addi-
tionally, charybdotoxin administration alone or in combination with
ascorbic acid did not modify the locomotor activity of mice in the open-
ﬁeld (Fig. 2B), since two-way ANOVA revealed no signiﬁcant differences
for ascorbic acid [F(1,23)=0.51, P=0.48], charybdotoxin [F(1,23)=
0.83, P>0.26] and ascorbic acid×charybdotoxin interaction [F(1,23)=
1.27, P=0.26].
The results presented in Fig. 2C show the effect of apamin (a small-
conductance calcium-activated K+ channel blocker, 10 pg/site, i.c.v.) in
producing a synergistic anti-immobility effect with a sub-effective dose
of ascorbic acid in the TST. The two-wayANOVA revealed signiﬁcant dif-
ferences for ascorbic acid [F(1,28)=6.94, P=0.01], apamin [F(1,28)=
7.01, P=0.01] and ascorbic acid×apamin interaction [F(1,28)=
21.21, Pb0.01].As revealed by the post-hoc analysis, the administra-
tion of apamin, administered at a dose that did not produce an
antidepressant-like effect in the TST, produced a synergistic effect
when combined with a sub-effective dose of ascorbic acid in the
TST. Additionally, apamin administration alone or in combination
with ascorbic acid did not modify the locomotor activity in the
open-ﬁeld (Fig. 2D). The two-way ANOVA revealed no signiﬁcant
differences for ascorbic acid [F(1,27)=2.90, P=0,09], apamin
[F(1,27)=2.77, P=0.10] and ascorbic acid×apamin interaction
[F(1,27)=0.37, P=0.54].
3.2. Effects of K+ channel openers on ascorbic acid-induced anti-
immobility effects in the TST and in the number of crossings in the
open-ﬁeld test
Fig. 3A shows that the treatment of mice with cromakalim (a K+
channel opener, 10 μg/site, i.c.v.) was able to reverse the antidepressant-ite, i.c.v.) in combination with a sub-effective dose of ascorbic acid (0.1 mg/kg, p.o.) in
s mean±S.E.M. (n=7–8). * Pb0.01 compared with the vehicle-treated control group.
Fig. 2. Effect of the treatment of mice with charybdotoxin (25 pg/site, i.c.v.) or apamin (10 pg/site, i.c.v.) in combination with a sub-effective dose of ascorbic acid (0.1 mg/kg, p.o.) in
the TST (panels A and C) and in the open-ﬁeld test (panels B and D). Values are expressed as mean±S.E.M. (n=7–8). *Pb0.01 compared with the vehicle-treated control group.
Fig. 3. Effect of the treatment of mice with cromakalim (10 μg/site, i.c.v.) or minoxidil (10 μg/site, i.c.v.) on the ascorbic-induced (1 mg/kg, p.o.) antidepressant-like effect in the TST
(panels A and C) and on locomotor activity in the open-ﬁeld test (panels B and D). Values are expressed as mean±S.E.M. (n=7–8). *Pb0.01 compared with the vehicle-treated
control group. #Pb0.05 compared with the same group pre-treated with vehicle.
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Fig. 4. Effect of the treatment of mice with cromakalim (10 μg/site, i.c.v.) on the synergis-
tic antidepressant-like effect induced by the combined administration of ascorbic acid
(0.1 mg/kg, p.o.) and 7-nitroindazole (25 mg/kg, i.p.) in the TST (panel A) and on loco-
motor activity in the open-ﬁeld test (panel B). Values are expressed as mean±S.E.M.
(n=7–8). *Pb0.01 compared with the vehicle-treated control group. #Pb0.05 com-
pared with the same group pre-treated with vehicle.
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revealed signiﬁcant differences for cromakalim [F(1,25)=6.50, P=0.01]
and ascorbic acid×cromakalim interaction [F(1,25)=13.58, Pb0.01], but
not amain effect of ascorbic acid [F(1,25)=1.31, P=0.26]. Post-hoc anal-
ysis indicated that the treatmentwith cromakalim abolished the decrease
in the immobility time produced by ascorbic acid in the TST. Regarding lo-
comotor activity, as showed in the Fig. 3B, charybdotoxin administration
alone or in combination with ascorbic acid did not produce any change
in the ambulatory behavior of mice, since the two-way ANOVA did not
show signiﬁcant differences for ascorbic acid [F(1,26)=0.06, P=0,80],
cromakalim [F(1,26)=0.11, P=0.73] and ascorbic acid×cromakalim in-
teraction [F(1,26)=2,32, P=0.13].
Fig. 3C indicates that minoxidil (a K+ channel opener, 10 μg/site,
i.c.v.) also reversed the antidepressant-like effect of ascorbic acid
(1 mg/kg, p.o.) in the TST. The two-way ANOVA revealed signiﬁcant
differences for ascorbic acid [F(1,26)=5.61, P=0.02], minoxidil
[F(1,26)=8.63, Pb0.01] and ascorbic acid×minoxidil interaction
[F(1,26)=7.38, P=0.01]. Post-hoc analysis indicated that the treat-
ment with minoxidil abolished the reduction in immobility time pro-
duced by ascorbic acid in the TST. Fig. 3D shows that minoxidil
administration alone or in combination with ascorbic did not change
the locomotor activity of mice, since the two-way ANOVA did not
show signiﬁcant differences for ascorbic acid [F(1,26)=0.42, P=0,52],
cromakalim [F(1,26)=1.04, P=0.31] and ascorbic acid×cromakalim
interaction [F(1,26)=3,42, P=0.07].
3.3. Effect of cromakalim on the synergistic antidepressant-like effect
induced by the combined administration of ascorbic acid and 7-
nitroindazole
As shown in Fig. 4A, the administration of 7-nitroindazole
(25 mg/kg i.p., a speciﬁc neuronal NOS inhibitor) in combination with
ascorbic acid (0.1 mg/kg, p.o.) produced an antidepressant-like effect
in the TST. Administration of cromakalim (a K+ channel opener,
10 μg/site, i.c.v.) was able to abolish the synergistic antidepressant-
like effect elicited by the combined administration of ascorbic acid
and 7-nitroindazole. The three-way ANOVA showed signiﬁcant differ-
ences for ascorbic acid×7-nitroindazole×cromakalim interaction
[F(1,49)=22.07, Pb0.01]. Post-hoc analysis indicated that the
treatment with cromakalim blocked the decrease in immobility
time in the TST produced by combined administration of ascorbic
acid and 7-nitroindazole. Moreover, ascorbic acid, 7-nitroindazole
and cromakalim administration alone or in combination did not
modify the locomotor activity in the open-ﬁeld (Fig. 4B). The
three-way ANOVA revealed no signiﬁcant differences for ascorbic
acid×7-nitroindazole×cromakalim interaction [F(1,49)=0.87,
P=0.35].
4. Discussion
In the present study, through the use of several pharmacological
tools, we provide evidence that themodulation of K+ channels contrib-
utes to the antidepressant-like effect of ascorbic acid in the TST. Treat-
ment of mice with sub-effective doses of different blockers of K+
channels was able to produce a synergistic antidepressant-like effect
with a sub-effective dose of ascorbic acid in the TST, whereas the treat-
ment of animals with cromakalim andminoxidil, pharmacological com-
pounds able to open K+ channels, abolished the antidepressant-like
effect elicited by an effective dose of ascorbic acid. In addition, the ad-
ministration of cromakalim was able to abolish the synergistic
antidepressant-like effect elicited by the combined administration of
ascorbic acid and 7-nitroindazole, an inhibitor of neuronal NOS activity.
It is important to note that neither ascorbic acid nor K+ channel modu-
lators and 7-nitroindazole, administered alone or in combination, affect-
ed the spontaneous locomotion, ruling out the hypothesis that theresults observed in the TST could be inﬂuenced by differences in loco-
motor behavior.
The precise molecular mechanisms responsible for the antidepres-
sant action of ascorbic acid are still not fully understood, however, our
group has previously demonstrated that it has antidepressant proper-
ties in mice, as evidenced by its ability to decrease the immobility
time in the TST (Binfaré et al., 2009; Moretti et al., 2011) and to abol-
ish the depressive-like behavior induced by chronic unpredictable
stress in mice (Moretti et al., 2012). Besides, it was demonstrated
that the mechanism by which ascorbic acid exerts its anti-
immobility effect in the TST in mice involves an interaction with
monoaminergic systems (Binfaré et al., 2009), and an inhibition of ei-
ther the L-arginine-NO pathway or NMDA receptors (Moretti et al.,
2011). Noteworthy, these targets have been progressively reported
to be implicated in the pathophysiology of depression (Elhwuegi,
2004; Harkin et al., 1999). In the present work, we extend our previ-
ous ﬁndings by indicating that the antidepressant-like effect observed
after an acute administration of ascorbic acid in the TST might be also
related to a regulation of neuronal excitability via modulation of dif-
ferent types of K+ channels.
K+ channels can be classiﬁed by their mechanism of activation-
inactivation. The K+ channel blockers glibenclamide, charybdo-
toxin and apamin are known to selectively block ATP-sensitive,
large- and intermediate-conductance calcium-activated and small-
conductance calcium-activated K+ channels, respectively (Gehlert
and Gackenheimer, 1993). Apamin, a peptide contained in the
venom of the honey bee Apis mellifera (Stocker, 2004), selectively
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TEA is classiﬁed as a non selective blocker of K+ channels, since
it blocks different types of K+ channels in neurons including
calcium-activated and voltage-dependent K+ channels (Cook and
Quast, 1990; Halliwell, 1990). Previous studies have demonstrated
that the K+ channel functionally appears fundamental in the mod-
ulation of the mouse immobility time in the forced swimming test,
a widely used test to predict the antidepressant action of drugs in
humans. In mice, an antidepressant-like effect was produced by
blocking the K+ channels, whereas a depressive-like effect was
obtained by opening K+ channels (Galeotti et al., 1999; Kaster et
al., 2005).
Despite the fact that modulation of the K+ channels can have con-
siderable implications on neural function, the actions of ascorbic acid
on these channels have not been studied thoroughly. Ascorbic acid
has been previously shown to reverse the hydrogen peroxide-
induced inhibition of inward K+ currents in Vicia guard cells (Zhang
et al., 2001). Moreover, ascorbic acid was reported to reduce the tran-
sient and sustained K+ currents in Drosophila neurons, which could
increase neuronal excitability (Alshuaib and Mathew, 2006). In the
present study, an important role played by ATP-sensitive and
calcium-activated K+ channels in the antidepressant-like effect of
ascorbic acid in the TST was shown. This conclusion is derived from
the fact that the administration of sub-effective doses of TEA, apamin,
charybdotoxin, and glibenclamide in combination with a sub-effective
dose of ascorbic acid provoked a robust reduction in the immobility
time, indicative of an antidepressant-like behavioral proﬁle. Altogether,
these results suggest that the blockade of ATP-sensitive and calcium-
activated K+ channels contributes to the antidepressant-like effect of
this vitamin in the TST.
Rosati et al. (1998) showed that glibenclamide, an ATP-sensitive
K+ channel inhibitor, blocks neural delayed rectiﬁer K+ currents.
On the other hand, Ca+-dependent K+ conductance plays a major
role in regulating the frequency of repetitive neuronal discharges
and accelerating spike repolarization (Szente et al., 1988). Charyb-
dotoxin blocks K+ movement by occluding the pore of the Ca2+ acti-
vated K+ channel, signiﬁcantly prolonging the duration of the action
potential. Further, while there is less efﬂux of K+ the membrane po-
tential rises, and hence the likelihood of initiating an action potential
increases, causing hyperexcitability of the nervous system. It was
demonstrated that TEA increases the ventricular threshold potential,
prolongs the action potential and at high concentration (3 mM) in-
creases its amplitude (Doggrell and Bishop, 1996), effects that could
be due to the blocking of inward-rectifying or the delayed outward-
rectifying K+ channels (Cook and Quast, 1990). In light of these con-
siderations and taking into account that K+ channel blockers may in-
crease the excitability of central circuits, it is plausible to propose that
the potentiation of the antidepressant-like effect of ascorbic acid in-
duced by K+ channel blockers (TEA, apamin, charybdotoxin, and
glibenclamide) observed in the present study may be due to an inhi-
bition of the hyperpolarization elicited by this vitamin, thus leading
to an increased excitatory response. However, it remains to be
established if ascorbic acid shares with the potassium channel inhib-
itors the same mechanisms mentioned above.
It was reported that the stimulation of 5-hydroxytryptamine (5-HT)
receptors can affect several types of K+ channels in central neurons
(Bobker and Williams, 1990) and, consistent with this notion, there is
substantial evidence indicating an association between K+ channels
and the mechanism of action of antidepressants, especially those relat-
ed to the 5-HT system, including ﬂuoxetine, sertraline and venfalaxine
(Bortolatto et al., 2010; Choi et al., 2004; Inan et al., 2004). Recent ﬁnd-
ings indicate that these antidepressant drugs are potent inhibitors of K+
channels, affecting the excitability of neurons (Choi et al., 2004).
Moreover, it has been suggested that the blockade of K+ channels en-
hances the basal release of 5-HT in rat hippocampal slices (Schechter,
1997). Hence, the synergistic action of the K+ channel blockers andascorbic acid in the TST could be dependent on the activation of the se-
rotonergic system. This hypothesis is in agreement with the data pres-
ented by Binfaré et al. (2009), which demonstrated that the
administration of NAN-190 (a 5-HT1A receptor antagonist), ketanserin
(a 5-HT2A/2C receptor antagonist) and MDL72222 (a 5-HT3 receptor an-
tagonist) prevented the antidepressant-like effect of ascorbic acid in the
mouse TST.
The involvement of the L-arginine-NO-cGMP pathway has been
extensively reported to be implicated in the pathophysiology of de-
pression (Dhir and Kulkarni, 2001). Various drugs known to produce
an antidepressant-like action in the animal models of behavioral de-
spair are recognized to modulate this signaling pathway (Brocardo
et al., 2008; Rosa et al., 2003; Zomkowski et al., 2010). Of note, several
studies have reported that NO and cGMP can activate different types
of K+ channels (Bolotina et al., 1994; S.Y. Jeong et al., 2001; Shin et al.,
1997), and the inhibition of these channels might represent an im-
portant role in the mechanisms involved in depressive disorders
(Fernandes et al., 2002; Inan et al., 2004; Kaster et al., 2005). An inter-
esting ﬁnding of the present study is that the administration of
cromakalim (a K+ channel opener, 10 μg/site, i.c.v.) was able to abol-
ish the synergistic antidepressant-like effect elicited by the combined
administration of ascorbic acid and 7-nitroindazole, an inhibitor of
neuronal NOS activity. This result suggests that an indirect blockade
of the K+ channels by ascorbic acid via the NMDA-L-arginine-NO
pathway could account for the behavioral results observed in the
present study. In view of these and previous results found by our
group indicating that the antidepressant-like effect of ascorbic acid
is mediated by inhibition of NMDA receptors and NO synthesis
(Moretti et al., 2011), we can suggest that the blockade of K+ chan-
nels may be a consequence of the inhibition of NMDA receptors and
NO production induced by ascorbic acid. However, the possibility
that ascorbic acid also causes a direct inhibition of these channels
cannot be ruled out.
Further reinforcing the assumption that the antidepressant-like
effect of ascorbic acid involves the inhibition of K+ channels, treat-
ment of mice with the K+ channel openers, cromakalim and minoxi-
dil abolished the decrease in the immobility time (antidepressant-like
effect) induced by an effective dose of ascorbic acid in the TST. These
results support the involvement of K+ channels in the antidepressant-
like effect of ascorbic acid in mice TST and are in accordance with stud-
ies showing that channel openers antagonize the anti-immobility effect
of antidepressants such as imipramine, amitriptyline, desipramine,
paroxetine and venfalaxine in the FST (Bortolatto et al., 2010; Redrobe
et al., 1996).
5. Conclusion
The present study demonstrates that the pretreatment of mice
with different K+ channel blockers produces an antidepressant-like
action with a sub-effective dose of ascorbic acid, whereas the treat-
ment with K+ channel openers abolished the antidepressant-like ef-
fect produced by an effective dose of this vitamin. Given that the
pharmacological modulation of these channels may be a putative
strategy in controlling central nervous system disorders, including
depression, and considering our results indicating that the modulato-
ry effects of ascorbic acid on neuronal excitability, via inhibition of K+
channels, we can suggest that this vitamin can be a promising agent
to assist in the treatment of depression. However, additional studies
aiming at investigating other mechanisms by which ascorbic acid in-
duces antidepressant-like effects are essential.
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